Overview
Mirna Therapeutics, Inc., is a biopharmaceutical research and development company focused
on miRNA-directed human therapies. The Company was founded in late 2007 to accelerate the drug
discovery and development program that began in 2002 at Ambion, Inc., The RNA Company, and was
continued at Asuragen, Inc., a leading company developing diagnostic products based on RNA and DNA.
Mirna has identified numerous tumor suppressor miRNAs that play key roles in preventing normal cells
from becoming cancerous. These miRNAs are reduced or lost in virtually all cancers. Mirna’s therapeutic
strategy is to bring this tumor suppressor activity back into target tissue cells by administering
mimics of natural miRNAs, an approach known as “miRNA Replacement Therapy”. Replacement of one or
more of these key miRNAs results in a strong therapeutic response in animals, supporting the emerging
consensus that the systemic administration of miRNAs may be a clinically viable anticancer therapeutic
strategy. Mirna is creating value by broadening its base of miRNA intellectual property, identifying new
miRNA therapeutic targets, and advancing the development of several miRNA drug leads to validated drug
candidates directed against cancerous disease. Mirna is pursuing partnerships with pharmaceutical and
biotechnology companies to leverage its intellectual property and expand the Company’s development pipeline
in oncology which includes traditionally structured drug discovery and development collaborations, research
and technology collaborations, and intellectual property licenses. The Company’s intellectual property and
research platforms also apply to diseases other than cancer, providing opportunities for partnerships
outside the cancer space. Please contact us at busdev@mirnarx.com to inquire about partnering opportunities.